Pharmaceutics International
Multinational contract formulation development, clinical trial materials, and commercial manufacturing company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
Related Content
Pharmaceutics International, Inc. (Pii) is a contract development and manufacturing organization (CDMO) that provides comprehensive services for the pharmaceutical industry. With over 25 years of experience, Pii specializes in the development and cGMP (current Good Manufacturing Practice) manufacturing of liquid, suspension, and lyophilized parenterals, as well as oral liquids, suspensions, and solid dosage forms. The company serves a diverse range of clients, including pharmaceutical and biotechnology companies, offering tailored solutions to meet unique project needs.
Pii operates in the highly regulated pharmaceutical market, focusing on parenteral drug development and injectable processing. The company's business model revolves around providing end-to-end solutions, from early-stage development to commercial manufacturing. Pii generates revenue through service contracts, offering expertise in areas such as dosage form formulation, aseptic filling, lyophilization, clinical trial manufacturing, and commercial manufacturing.
The company is committed to transparency, dedication, and integrity, ensuring that every partnership is built on trust and mutual success. Pii also offers specialized services like high potent HPAPI (Highly Potent Active Pharmaceutical Ingredients) handling, cytotoxic drug processing, and DEA Schedule I-V controlled substances management. Additionally, Pii provides regulatory support, analytical quality assurance, and serialization equipment to ensure compliance with industry standards.
Pii's recent expansion in sterile manufacturing operations aims to deliver high-quality, small and medium batch aseptic fill finish efficiently and on accelerated timelines. The company also offers a $100,000 grant for First in Human Project Funding, encouraging innovation in therapeutic development.
Keywords: CDMO, parenteral drugs, cGMP manufacturing, aseptic filling, lyophilization, HPAPI, cytotoxic drugs, regulatory support, clinical trial manufacturing, commercial manufacturing.